HK1114614A1 - Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7- [3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same 4-[(24--5-)]-6--7-[3-(4--1-)]-3- - Google Patents

Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7- [3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same 4-[(24--5-)]-6--7-[3-(4--1-)]-3-

Info

Publication number
HK1114614A1
HK1114614A1 HK08110155.2A HK08110155A HK1114614A1 HK 1114614 A1 HK1114614 A1 HK 1114614A1 HK 08110155 A HK08110155 A HK 08110155A HK 1114614 A1 HK1114614 A1 HK 1114614A1
Authority
HK
Hong Kong
Prior art keywords
quinolinecarb
onitrile
piperazinyl
methoxyphenyl
propoxy
Prior art date
Application number
HK08110155.2A
Other languages
English (en)
Chinese (zh)
Inventor
Marc Sadler Tesconi
Gregg Feigelson
Henry Strong
Hong Wen
Original Assignee
惠氏有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37103295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1114614(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 惠氏有限責任公司 filed Critical 惠氏有限責任公司
Publication of HK1114614A1 publication Critical patent/HK1114614A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
HK08110155.2A 2005-07-01 2008-09-12 Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7- [3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same 4-[(24--5-)]-6--7-[3-(4--1-)]-3- HK1114614A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69638105P 2005-07-01 2005-07-01
PCT/US2006/025160 WO2007005462A1 (en) 2005-07-01 2006-06-28 Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same

Publications (1)

Publication Number Publication Date
HK1114614A1 true HK1114614A1 (en) 2008-11-07

Family

ID=37103295

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08110155.2A HK1114614A1 (en) 2005-07-01 2008-09-12 Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7- [3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same 4-[(24--5-)]-6--7-[3-(4--1-)]-3-

Country Status (25)

Country Link
US (2) US7767678B2 (xx)
EP (1) EP1902029B2 (xx)
JP (1) JP2009500332A (xx)
KR (1) KR20080028386A (xx)
CN (1) CN101248047A (xx)
AR (1) AR054505A1 (xx)
AU (1) AU2006266045A1 (xx)
BR (1) BRPI0613574A2 (xx)
CA (1) CA2613053C (xx)
CR (1) CR9596A (xx)
DK (1) DK1902029T4 (xx)
EC (1) ECSP078063A (xx)
ES (1) ES2449197T5 (xx)
GT (1) GT200600282A (xx)
HK (1) HK1114614A1 (xx)
IL (1) IL188483A0 (xx)
MX (1) MX2008000384A (xx)
NO (1) NO20080051L (xx)
PA (1) PA8685101A1 (xx)
PE (1) PE20070190A1 (xx)
PL (1) PL1902029T5 (xx)
PT (1) PT1902029E (xx)
RU (1) RU2007148072A (xx)
TW (1) TW200740797A (xx)
WO (1) WO2007005462A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102470109A (zh) * 2009-07-02 2012-05-23 惠氏有限责任公司 3-氰基喹啉片剂制剂及其应用
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
CN104447541A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 博舒替尼化合物
WO2015123758A1 (en) * 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
WO2015149727A1 (en) 2014-04-02 2015-10-08 Zentiva, K.S. Novel solid phases of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 -piperazinyl)propoxy]-3-quinolinecarbonitrile
CN105384686B (zh) * 2014-09-04 2019-07-26 连云港润众制药有限公司 一种博舒替尼结晶方法
WO2016034150A1 (zh) * 2014-09-04 2016-03-10 正大天晴药业集团股份有限公司 博舒替尼及其结晶的制备方法
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
WO2017134679A1 (en) * 2016-02-03 2017-08-10 Msn Laboratories Private Limited Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof
WO2017145089A1 (en) * 2016-02-23 2017-08-31 Sun Pharmaceutical Industries Limited Crystalline form x of bosutinib
CN105646345A (zh) * 2016-03-16 2016-06-08 浙江海正药业股份有限公司 博舒替尼的新晶型及其制备方法
CN106187886B (zh) * 2016-07-06 2019-04-16 山东创新药物研发有限公司 一种制备高纯度伯舒替尼一水合物的方法
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CN110317168A (zh) * 2018-03-30 2019-10-11 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2020209843A1 (en) 2019-04-09 2020-10-15 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
CN112321505B (zh) * 2019-10-25 2022-08-23 杭州中美华东制药有限公司 一种伯舒替尼晶型及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6432979B1 (en) * 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
MXPA06001590A (es) * 2003-08-19 2006-05-19 Wyeth Corp Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos.
WO2005065074A2 (en) * 2003-09-09 2005-07-21 Temple University Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
WO2005047259A1 (en) * 2003-11-06 2005-05-26 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
US7910211B2 (en) * 2005-06-20 2011-03-22 E.I. Du Pont De Nemours And Company Process for the production of multi-layer coatings
BRPI0611977A2 (pt) 2005-06-24 2010-10-13 Wyeth Corp uso de um composto
US8520232B2 (en) * 2006-03-31 2013-08-27 Konica Minolta Laboratory U.S.A., Inc. Print job analyzing method and apparatus with print device recommendation functions

Also Published As

Publication number Publication date
CR9596A (es) 2008-03-06
GT200600282A (es) 2007-02-14
US7767678B2 (en) 2010-08-03
DK1902029T4 (da) 2022-02-28
NO20080051L (no) 2008-01-29
TW200740797A (en) 2007-11-01
US20100324066A1 (en) 2010-12-23
US8445496B2 (en) 2013-05-21
WO2007005462A1 (en) 2007-01-11
ES2449197T3 (es) 2014-03-18
EP1902029A1 (en) 2008-03-26
CA2613053C (en) 2015-11-24
AR054505A1 (es) 2007-06-27
CA2613053A1 (en) 2007-01-11
MX2008000384A (es) 2008-03-07
BRPI0613574A2 (pt) 2016-11-16
EP1902029B2 (en) 2022-02-16
ES2449197T5 (es) 2022-04-28
PT1902029E (pt) 2014-03-05
KR20080028386A (ko) 2008-03-31
DK1902029T3 (en) 2014-02-17
AU2006266045A1 (en) 2007-01-11
EP1902029B1 (en) 2014-01-08
PL1902029T5 (pl) 2022-08-29
US20070015767A1 (en) 2007-01-18
PA8685101A1 (es) 2007-01-17
PL1902029T3 (pl) 2014-08-29
IL188483A0 (en) 2008-04-13
PE20070190A1 (es) 2007-03-20
RU2007148072A (ru) 2009-08-10
ECSP078063A (es) 2008-01-23
JP2009500332A (ja) 2009-01-08
CN101248047A (zh) 2008-08-20

Similar Documents

Publication Publication Date Title
IL188483A0 (en) Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
HRP20170634T1 (hr) Kristalni oblici od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
ZA200306335B (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
IL192241A0 (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof
ZA200509103B (en) Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamideor salts thereof
ZA200803527B (en) Crystals of laquinimod sodium, and process for the manufacture thereof
NO20054070D0 (no) 4-[(2,4-diklor-5-metoksyfenyl)amino]-6-alkoksy-3-kinol inkarbonitriler for behandling av isjemisk skade.
IL185785A0 (en) Certain substituted amides, method of making, and method of use thereof
ZA200706697B (en) 3, 4-Substituted pyrrolidine derivatives for the treatment of hypertension
EP1968943A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF MONTELUCASTAST AND THE PHARMACEUTICALLY SAFE SALTS
EP1863769A4 (en) HSP90 INHIBITORS, METHOD FOR THE PRODUCTION THEREOF AND THEIR APPLICATIONS
HUP0500920A2 (en) Oxadiazole derivatives, process for their preparation and their use
IL179068A0 (en) Substituted enaminones, their derivatives and uses thereof
PL1786759T3 (pl) Nowe pochodne 3,5-seko-4-norcholestanowe i ich zastosowanie
HK1123551A1 (en) Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl) amino benzonitrile
ZA200903981B (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy-3-bromo-6-methyl-2-oxopyridin-1(2h)-yl)-n,4-dimethyl-benzamide
AU2003272007A1 (en) Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
AU2003267281A8 (en) Paper compositions, imaging methods and methods for manufacturing paper
EP1534089A4 (en) QUALITATIVELY HIGH-QUALITY DRIED BOUILLON AND METHOD FOR THE PRODUCTION THEREOF
IL182445A0 (en) Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfona mido-dibenzo[b,d]furan-1-caboxamide
SI1902029T1 (sl) Kristalne oblike 4-((2,4-dikloro-5-metoksifenil)amino)-6-metoksi-7-(3- (4-metil-1-piperazinil)propoksi)-3-kinolinkarbonitril in metode za pripravo le-teh
TWI365874B (en) One-pot process for the preparation of 1,2-benz-isoxazole-3-methanesulfonamide
PL363419A1 (en) Orthopaedic curve corrector
ZA200708108B (en) Certain substituted amides, method of making, and method of use thereof
IL174063A0 (en) Crystalline form of gatifloxacin

Legal Events

Date Code Title Description
AM43 Amendment of standard patent following opposition or revocation proceedings in the designated patent office (acc. sect 43 patent ordinance)